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Methamphetamine is a powerful, highly addictive central nervous system 
stimulant that is associated with deleterious health outcomes. In particular, there is 
evidence from clinical treatment samples and criminal justice populations that 
methamphetamine use is associated with depression, however this association has yet to 
be investigated in a nationally representative sample. Given that young adults are the 
group most prone to methamphetamine use, this study used a total of 8,688 respondents 
from Waves III (2001-02; ages 18-28) and IV (2007-08; ages 24-34) of the National 
Study of Adolescent Health (Add Health) to examine whether methamphetamine use 
(past year use at Wave III) was associated with depression, as measured by the Center for 
Epidemiologic Studies Depression Scale (CES-D). This study also evaluated whether 
gender, functional poverty status, polydrug use, and childhood maltreatment moderated 
the association between methamphetamine use and depression.  
Logistic regressions were used to determine the odds ratios (OR) and 95% 
confidence intervals (95% CI) in unadjusted and adjusted analyses (controlling for 
gender, age, race/ethnicity, US region, functional poverty status, childhood maltreatment, 
	  
polydrug use, and depression at Wave III).  Results indicated that in the general 
population, methamphetamine users have increased odds of becoming depressed (OR: 
2.13, 95% CI: 1.38-3.27) and controlling for covariates, including Wave III depression, 
methamphetamine use independently predicted later depression (OR: 1.81, 95% CI: 1.12-
2.92). None of the potential moderator variables tested had an effect on the association. 
These findings indicate that longitudinally, methamphetamine users are at an increased 
risk for depression, regardless of other factors and perhaps drug prevention and treatment 
programs for methamphetamine use should focus more on decreasing depression in this 
population. This study provides a broader understanding of the relationship between 
methamphetamine use and depression in a nationally representative sample, though 
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  CHAPTER 1: INTRODUCTION 
Methamphetamine is a highly addictive psychostimulant associated with 
significant physical, psychological and social consequences consisting of chronic illness 
and physical health problems (Gonzales, Mooney & Rawson, 2010); impaired cognitive 
functioning (Henry, Minassian & Perry, 2010; Meredith, Jaffe, Ang-Lee & Saxon, 2005; 
Scott, Woods, Matt, Meyer, Heaton et al., 2007; Simon, Domier, Sim, Richardson, 
Rawson, et al., 2002); risky sexual behaviors, such as increased sexual activity and 
inconsistent condom use (Darke, Kaye, McKetin & Duflou, 2008; Degenhardt, Coffey, 
Moran, Carlin & Patton, 2007; Molitor, Ruiz, Flynn, Mikanda, Sun, et al., 1999; Semple, 
Patterson & Grant, 2004; Zule, Costenbader, Meyer & Wechsberg, 2007); and psychiatric 
consequences, including psychosis, anxiety disorders, depression and suicide (Darke et 
al., 2008; Dyer & Cruickshank, 2005; Glasner-Edwards et al., 2008; Kalechstein et al., 
2000; Marshall & Werb, 2010; Meredith, Jaffe, Ang-Lee, & Saxon, 2005; Salo, et al., 
2011; Shoptaw et al., 2003; Zweben et al., 2004).  
Specifically, depression is the most common psychiatric disorder associated with 
methamphetamine use (Glasner-Edwards et al., 2008; Nakama et al., 2008; Semple, 
Zians, Strathdee & Patterson, 2007; Sutcliffe et al., 2009; Zweben et al., 2004). Rates can 
reach as high as 68% of female and 50% of male methamphetamine users (Zweben et al., 
2004). Depression, alone, is a significant public health issue, but for substance users, the 
effects can be especially dire; ithas been linked to early treatment dropout (Curran, 
Kirchner, Worley, Rookey & Booth, 2002) and poorer outcomes overall (e.g., relapse) 
(McLellan, Luborsky, Woody, O'Brien & Druley, 1983). 
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Statement of the Problem 
Although the association between methamphetamine use and depression is well 
established, much of the research involves populations in treatment or in a criminal 
justice setting. It has been suggested that prevalence estimates obtained from populations 
in treatment may not accurately represent levels of depression among methamphetamine 
users who are not in treatment (Semple, Patterson & Grant, 2005). Further, it is necessary 
to study this relationship in the general population (as opposed to treatment or criminal 
justice populations) in order to truly identify the potential impact of methamphetamine 
use on depression. Given the negative health consequences of both methamphetamine use 
and depression, it is important to understand the longitudinal association between 
methamphetamine use and depression and to determine to what degree other variables 
may effect this association. Lastly, methamphetamine use generally is initiated in young 
adulthood (mean age of first use is 19.3 years) (SAMHSA, 2010), and young adults (ages 
18-26) are the group most prone to use (SAMHSA, 2006) therefore it is important to 
examine this issue in an appropriate sample of young adults.  
Significance of the Study 
The purpose of the current study was to examine the longitudinal association 
between methamphetamine use and depression. Specifically, data collected at Wave III 
(ages 18 to 28) and Wave IV (ages 24 to 34) from The National Study of Adolescent 
Health (Add Health), a nationally representative longitudinal survey, was analyzed to 
investigate whether methamphetamine use (past year use at Wave III, representing young 
adulthood) is associated with depression six years later, as measured by the Center for 
Epidemiologic Studies Depression Scale (CES-D). Logistic regression was used to 
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determine the odds ratios (ORs) and 95% confidence intervals (95% CIs) in unadjusted 
and adjusted analyses (controlling for gender, age, race/ethnicity, US region, functional 
poverty status, childhood maltreatment, polydrug use, and Wave III depression). An 
interaction term was created and added to the model to test modification of effect by 
gender, functional poverty status, childhood maltreatment, and polydrug use.  
Examining factors that may affect the relationship between methamphetamine use 
and depression will likely provide a clearer understanding and enhance our ability to 
develop and deliver targeted interventions for both prevention and treatment purposes.  
Research Questions 
This study used Waves III (2001-02; ages 18 to 28) and IV (2007-08; ages 24 to 34) of 
Add Health to examine the following research questions:  
1. What is the longitudinal association between methamphetamine use at 
Wave III (2001-02) and depression at Wave IV (2007-08)? 
2. Is the relationship between methamphetamine use (at Wave III) and 
depression (at Wave IV) moderated by gender, functional poverty status, 
childhood maltreatment, or polydrug use? 
Definition of Terms 
The following are definitions of key terms that appear throughout the text.   
 Add Health - The National Longitudinal Study of Adolescent Health (Add Health) is 
a longitudinal study of a nationally representative sample of adolescents in the United 
States.  
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 Child maltreatment – Any act or failure to act, on the part of a parent or caregiver, 
that results in death, serious physical or emotional harm, sexual abuse, or exploitation 
(HHS, 2003). 
 Depression – A medical illness characterized by physical and emotional symptoms 
that interfere with an individual’s ability to work, sleep, study, eat, and enjoy 
pleasurable activities (NIMH, 2011). The Add Health interview uses a modified 9-
item version of the Center for Epidemiologic Studies Depression Scale (CES-D) to 
measure depression. 
 Methamphetamine – A powerful, highly addictive central nervous system stimulant. 
In Add Health, participants are asked specifically about ‘crystal meth’ use. Crystal 
meth is a highly pure, illicitly produced form of methamphetamine that can be 
smoked, snorted, injected, or taken orally. Until 2006, the National Survey on Drug 
Use and Health (NSDUH; SAMHSA, 2010) used the general term 
“methamphetamine” rather than crystal meth specifically, and questions pertaining to 
use were asked as part of the module on nonmedical use of prescription-type drugs 
(which was appropriate back when diverted pharmaceuticals were the primary type of 
methamphetamine used).Rutkowski and Maxwell (2009) believe that the Add Health 
designation of “crystal meth” produces a more accurate snapshot for the prevalence of 
use because it captures illicitly produced methamphetamine (Rutkowski & Maxwell, 
2009). 
 Polydrug use – The use of more than one illicit substance (e.g. marijuana, cocaine, 
methamphetamine) within a specified period of time. A broad definition may consider 
entire life history of substance use, whereas a more narrow definition may focus on 
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the past 12-months or 30-days. In this study, polydrug use is past year use of 
marijuana, cocaine, or heroin, and methamphetamine.  
 Substance abuse – The use of a substance to the extent that harmful consequences 
occur as a result of repeated use and/or substance dependence (NIDA, 2009).  
 Substance dependence - Substance dependence and addiction are synonymous terms. 
Addiction, as defined by the National Institute on Drug Abuse (NIDA), is a chronic 
disease characterized by compulsive drug seeking and abuse in spite of known 
adverse consequences, and by functional, sometimes long-lasting changes in the brain 
(NIDA, 2009).  
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CHAPTER 2: LITERATURE REVIEW 
Description of Methamphetamine 
Methamphetamine is a highly addictive, powerful central nervous system 
stimulant. As a methyl derivative of amphetamine, the chemical structure and effects of 
methamphetamine are similar to that of amphetamine, as they both increase stimulation 
of dopamine and norepinephrine receptors in the brain (Anglin, Burke, Perrochet, 
Stamper & Dawud- Nours, 2000). Similar to other amphetamine-type stimulants, 
methamphetamine is a controlled substance and a Schedule II class drug. The commonly 
used and street-acquired methamphetamine, typically found as white powder or 
translucent crystals, may be referred to as ‘ice,’ ‘crank,’ ‘tina,’ ‘speed,’ ‘glass,’ or ‘crystal 
meth’  (NIDA, 2006). Methamphetamine can be smoked; snorted; or consumed orally, 
rectally, and intravenously, though smoking methamphetamine is the most common route 
of administration (NIDA, 2006). The route of administration and dose ingested are 
directly related to the intensity, onset, and length of effects, and both smoking and 
injection use are more likely to lead to dependence (McKetin, Kelly & McLaren, 2006).  
Unlike imported drugs, such as cocaine and heroin, illicit methamphetamine is 
easy to manufacture using pharmaceutical, agricultural, and industrial products that are 
publicly available (Greene, Kerr & Braitberg, 2008). As a result, methamphetamine 
production often occurs in clandestine home laboratories (sometimes referred to as “meth 
labs”) that are typically operated by methamphetamine abusers (Hunt, 2006). These 
laboratories are often found in residential homes and present additional public health 
risks, as many chemicals used in the production and resulting by-products of “cooking” 
methamphetamine are hazardous and toxic, and thus dangerous to the community 
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surrounding the lab and any individuals in the home (OCOPS, 2002). For every pound of 
methamphetamine manufactured in a clandestine meth lab, an estimated five to six 
pounds of hazardous waste are produced (Hunt, Kuck & Truitt, 2006).  
Methamphetamine was first synthesized at the end of the 19th century by a 
Japanese pharmacologist, but it was not widely used until World War II, when Germany, 
Japan and the United States (US) supplied the drug for military use as it increased 
performance and endurance (Anglin, Burke, Perrochet, Stamper & Dawud- Nours, 2000). 
In the United States, the illicit market mainly consisted of diverted pharmaceuticals 
(misused prescription medication that was prescribed for the treatment of asthma) until 
the illicit production of methamphetamine emerged in the early 1960’s and use spread 
along the Pacific Coast as Bay Area motorcycle gangs controlled manufacturing and 
distribution (Anglin, et al., 2000). By 1980, simpler methods for home production were 
developed using an ephedrine-based reduction method (Anglin, et al., 2000) and at the 
same time, large quantities of a highly pure, crystallized form of methamphetamine 
(“crystal meth”) were smuggled into California from Mexico and distributed throughout 
the Southwestern and Midwestern states (Anglin, et al., 2000).  
During this period, methamphetamine use increased in Hawaii, as ‘ice’ began to 
be imported from Southeast Asia and the Philippines, and spread throughout the United 
States (Gonzales, Mooney & Rawson, 2010). Given the availability of the precursor 
chemicals, such as pseudoephedrine, used to produce methamphetamine and the relative 
ease of manufacture, in 2005, the US federal government enacted the Combat 
Methamphetamine Epidemic Act (CMEA), which limited the sale of products containing 
pseudoephedrine (e.g. over-the-counter cold medicine, Sudafed) (ONDCP, 2010). 
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Although there is evidence of a decrease in methamphetamine use since the passage of 
CMEA, methamphetamine producers have found ways around CMEA and the number of 
methamphetamine lab incidents involving law enforcement have increased; there were 
966 lab seizures nationwide in March 2009 compared to 596 incidents in March 2007 
(ONDCP, 2010). 
Effects of Methamphetamine Use 
Similar to other psychostimulants (e.g. cocaine), the immediate physiological 
response of methamphetamine intoxication includes increased alertness, physical activity, 
respiration, heart rate and blood pressure, and decreased appetite (NIDA, 2006). The 
“high” creates an elevated positive mood and feeling of euphoria that can last between 
eight-12 hours due to the 12-hour half-life of methamphetamine (Cho, Melega, 
Kuczenski, & Segal, 2001). In addition to intense euphoria, other positive reinforcing 
attributes of methamphetamine use include increased energy and alertness, heightened 
mental capacity, enhanced libido and decreased anxiety (Meredith et al., 2005). However, 
there are many negative health outcomes associated with repeated methamphetamine use, 
including insomnia, hyperthermia, stroke, stomach cramps, cardiac arrhythmia, and 
seizures (NIDA, 2009). Methamphetamine associated fatalities are most commonly 
attributed to pulmonary congestion, cerebrovascular hemorrhage (as a result of 
hypertension), acute cardiac failure or hyperpyrexia, though there is evidence that a 
significant number of deaths (possibly a greater proportion than the latter) arise from 
accidents, suicides and homicides resulting from behavioral and psychological 
disturbances from methamphetamine intoxication (Cruickshank & Dyer, 2009).  
Withdrawal from methamphetamine, often referred to as “the crash,” typically 
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results in more psychological discomfort than physical symptoms and usually includes 
depressed mood with severe dysphoria, anxiety, irritability, hypersomnia, fatigue and 
intense craving for the drug (Meredith, Jaffe, Ang-Lee & Saxon, 2005). The severity of 
these symptoms seems to be related to the frequency and intensity of use (Meredith et al, 
2005). Methamphetamine dependence is more strongly associated with injection use and 
smoking the drug, and it is hypothesized that many of the negative health consequences, 
such as those listed above, result from dependence due to long-term, frequent use 
(McKetin, Kelly & McLaren, 2006). In addition to frequency of use, potency of the drug 
may increase the likelihood of dependence (Darke, Kaye, McKetin & Duflou, 2008).  
Repeated methamphetamine use is also associated with decreased daily 
functioning, indicated by poor performance in a variety of areas, including cognitive 
tasks related to comprehension and planning, communication skills, and activities such as 
managing medication or participating in financial transactions (Henry, Minassian & 
Perry, 2010). Noninvasive brain imaging studies show that long-term methamphetamine 
abuse or dependence is linked to structural brain alterations and metabolic and 
neurotransmitter irregularities (Scott et al., 2007), which may underlie the observed 
association between methamphetamine use and impaired cognitive function and problems 
regulating emotions. Stimulants and other illicit drugs have previously been linked to 
neurocognitive changes; however, methamphetamine use is linked to distinctive 
impairments that endure during protracted abstinence (e.g. several months or more) 
(Meredith et al., 2005).  
In addition, compared to individuals who abuse other stimulants and illicit drugs, 
there is evidence that methamphetamine users develop different cognitive impairments 
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(Simon et al., 2002). Simon and colleagues (2002) conducted a study comparing 
neurocognitive performance between active methamphetamine users (n=40), cocaine 
users (n=40) and non-psychostimulant using controls (n=80), and found that though both 
methamphetamine and cocaine users have impairments in verbal memory, 
methamphetamine users also showed impairment on tasks measuring perceptual speed 
and information manipulation, suggesting they may have difficulty organizing 
information from more than one source and trouble switching points of view (Simon et 
al., 2002). Such deficits may translate to poor comprehension and ultimately affect one’s 
ability to participate in substance abuse treatment, understand legal proceedings, and 
follow regimens set by healthcare providers.  
Methamphetamine users often consume other substances (polydrug use), 
including alcohol, marijuana, other psychostimulants, and heroin, and though polydrug 
use is associated with poor clinical outcomes, there are specific harms that result from 
concomitant use of methamphetamine and other substances (Darke, Kaye, McKetin & 
Duflou, 2008). When methamphetamine is combined with other substances, such as 
alcohol, opiates, or cocaine, the toxicity of methamphetamine increases (Albertson, 
Derlet & Van Hoozen, 1999). Given the physiologic effects (e.g., increased heart rate and 
blood pressure), concomitant use of methamphetamine with other substances may 
increase risk of cardiac failure and death (Albertson, Derlet & Van Hoozen, 1999). 
There is evidence for additional negative health outcomes due to 
methamphetamine use and increased participation in unsafe sexual behaviors (e.g., 
multiple partners, unprotected intercourse) and other risky behaviors (i.e., sharing 
needles) (Darke et al., 2008; Degenhardt, Mathers, Guarinieri, Panda, et al., 2010; 
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Molitor et al., 1999; NIDA 2009; Semple, Patterson & Grant, 2004; Zule, Costenbader, 
Meyer & Wechsberg, 2007), increasing the likelihood of exposure to and transmission of 
Hepatitis C and human immunodeficiency virus (HIV). Research conducted by Semple, 
Patterson, and Grant (2004) compared the sexual behaviors of heterosexual 
methamphetamine users (n=181) recruited through community outreach programs to 
national data and found that on average, methamphetamine users were more sexually 
active, as they reported having vaginal intercourse 19.8 times per month (compared to the 
national average of 6.5 times per month) and participants averaged 11.2 sexual partners 
over 2-months, compared to the national average of 1.3 per year among heterosexual 
non-drug users. In addition, the rates of unprotected intercourse in a 2-month period 
(whether it was vaginal, anal, or oral sex) were also high in this population (mean number 
of times = 29.6, 13.1, 52.1, respectively), suggesting that methamphetamine users are at 
increased risk for contracting HIV and other sexually transmitted infections due to their 
increased sexual activity and high rates of unprotected sex (Semple, Patterson & Grant, 
2004).  
Similarly, Molitor and colleagues (1998) found that individuals who use 
methamphetamine are at greater risk for HIV-infection because they reported more 
sexual partners than non-methamphetamine users, and methamphetamine use was 
independently related to decreased condom use during intercourse (vaginal and anal), 
prostitution, and sex with injection drug users (Molitor, Truax, Ruiz, & Sun, 1998). Other 
research examining the relationship between methamphetamine use and HIV has found 
that HIV positive methamphetamine users have increased cognitive impairment and 
neuronal injury compared to HIV-positive non-users (Chang, Ernst, Speck, & Grob, 
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2005). In general, methamphetamine use is associated with increased rates of HIV, in part 
because of risky sexual behaviors, but also because methamphetamine use causes 
physiological changes that facilitate the transmission of HIV and conversion to acquired 
immunodeficiency syndrome (AIDS) (Venios & Kelly, 2010). As a vasoconstrictor, 
methamphetamine causes mucus membranes to dry, leading to the formation of genital 
ulcers, which increases the risk of transmission (Dickerson, Johnston, Delea, White, & 
Andrews, 1996). 
In addition to the consequences of use on physical health, methamphetamine is 
associated with psychiatric disorders including psychosis, anxiety, and depression 
(Darke, et al., 2008; Kalechstein et al., 2000; Marshall & Werb, 2010; Meredith et al., 
2005; Salo, Flower, Kielsein, et al., 2011; Zweben, et al., 2004). Studies have shown that 
approximately half of methamphetamine users have been diagnosed with a psychiatric 
disorder (e.g., major depressive disorder, bipolar disorder) as measured by the DSM-IV 
(Dyer & Cruickshank, 2005; Glasner-Edwards, Mooney, Marinelli-Casey et al., 2010; 
Shoptaw, et al., 2003), which is nearly double the national prevalence of diagnosed 
disorders (NIMH, 2011).  
Methamphetamine induced psychosis is typically transient, involving 
hallucinations and delusions (with persecutory themes) and may be accompanied by 
emotional instability, agitation, and hostility (Darke, et al., 2008). In a study by McKetin 
and colleagues (2006), methamphetamine users (n=309) were interviewed to assess the 
prevalence of psychosis within this population. Findings show that after excluding 
participants with a history of schizophrenia or other psychotic disorders, 18% of 
participants screened positive for clinically significant psychotic symptoms (McKetin, 
	   13	  
McLaren, Lubman & Hides, 2006). In a more recent study among methamphetamine 
users (n=526) at three years following substance abuse treatment, 13% of participants 
met criteria for a lifetime psychotic disorder (Glasner-Edwards, et al., 2010).   
Depression is the most common comorbid psychiatric disorder associated with 
methamphetamine use (Glasner-Edwards, et al., 2009; Nakama, et al., 2008; Semple, et 
al., 2007; Sutcliffe, et al., 2009; Zweben, et al., 2004). In substance abuse treatment 
populations, there is evidence that methamphetamine users have higher rates of 
depressive symptoms, that persist longer, compared to cocaine users (Rawson, et al., 
2002). In a study conducted with a large sample of methamphetamine users (n=1,061) in 
outpatient treatment, Zweben and colleagues (2004) found high levels of depression 
among both women (68%) and men (50%), and 27% of the entire sample reported a 
suicide attempt in their lifetime. In another study by Kalechstein and colleagues (2000), a 
sample of arrestees (n=1,580) was surveyed to assess the association between 
methamphetamine dependence and psychiatric symptoms. Findings showed that after 
controlling for demographic characteristics and dependence on other drugs in the 12-
months prior to the assessment, individuals dependent on methamphetamine were more 
likely to report symptoms of depression and thoughts of suicide, compared to individuals 
not reporting methamphetamine dependence (Kalechstein et al., 2000).  
Explanations for the Association Between Methamphetamine Use and Depression  
As previously noted, there is an established link between substance use and 
depression; however, there is still much debate over the etiology of depression among 
substance users. Early studies using animals to demonstrate the effect of 
methamphetamine use on the brain have shown that use induces profound and enduring 
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damage to dopamine cells (Preston, Wagner, Schuster & Seiden, 1985). More recent 
research employing neuroimaging techniques with humans has shown that chronic 
methamphetamine users exhibit reductions in dopamine neurotransmission (Volkow et 
al., 2001; Wang et al., 2004), which may be related to depression and anhedonia (Dunlop 
& Nemeroff, 2007). Dopamine appears to play a role in both methamphetamine use and 
depression, making the relationship particularly difficult to tease out. Another potential 
explanation for the observed neurobiological changes is that there are common factors, 
either genetic or environmental, that precede the onset and/or persistence of both 
substance use and depression (Kessler, 2004).  
Ecological Model  
To examine the relationship between methamphetamine use and depression and to 
identify and evaluate factors that may affect this relationship, this study used an 
ecological perspective, which is a model that allows for consideration of the multipart 
interplay between the individual and their environment. Specifically, the ecological 
model proposed by Bronfenbrenner (1977) places the individual in the center of several 
concentric circles, each representing a different level of interaction: microsystem 
(individual level), mesosystem (familial level), exosystem (community level) and 
macrosystem (societal level).  
According to Bronfenbrenner (1977), these system levels influence human 
development within a broad, ecological framework and the level of influence of different 
factors on the individual is represented by the proximity of each circle to the individual, 
representing direct or indirect factors. Application of an ecological model to understand 
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the association between methamphetamine use and depression allows for consideration of 
several variables at different levels of influence and how they may affect the association.  
Ecological Model and Moderators  
As previously noted, depression is common among methamphetamine users. 
However, to the author’s knowledge, there is no research establishing the temporal order 
of methamphetamine use and depression in a general population sample. Further, not all 
methamphetamine users experience depression and there is little research identifying 
other factors that may play a role in this relationship. Using the ecological model as a 
framework for choosing variables to examine, specific factors identified at each level of 
the model may act as modifiers of the relationship between methamphetamine use and 
depression (Figure 1).  
Figure 1. Adaptation of the Ecological Model: Potential Moderators of the Relationship 
Between Methamphetamine Use and Depression, including Covariates
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According to Baron and Kenny (1986), moderation occurs when the causal 
relationship between two variables differs as a function of the moderator. A moderator 
specifies on whom or under what conditions the independent variable will operate to 
produce the dependent variable (Baron & Kenny, 1986). Beginning at the micro level 
(i.e. individual), factors such as gender, race/ethnicity, and age may play a role in the 
relationship between methamphetamine use and depression.   
The microsystem consists of individual level factors that generate a social 
identity, including gender and polydrug use. Previous studies suggest that a gender 
difference exists in depression levels among methamphetamine users, as higher rates of 
depression are observed among female methamphetamine users (Glasner-Edwards, et al., 
2008; Zweban, et al., 2004). However, these findings may represent the general trend of 
higher rates of depression among women, compared to men, in the general population 
(Kessler, et al., 2005). Given the ambiguity, further exploration into how gender affects 
the association between methamphetamine use and depression is warranted.  
Polydrug use is common among substance users (Booth, Leukefeld, Falck, Wang, 
& Carlson, 2006; Byqvist, 2006; Darke, et al., 2008), particularly methamphetamine 
users (Brecht, Greenwell & Anglin, 2005). Further, polydrug use is associated with 
depression (Roiser & Sahakian, 2004). McKetin and colleagues (2011) found that among 
methamphetamine users in substance abuse treatment, concurrent polydrug use (in 
particular, use of cannabis and benzodiazepines) was significantly associated with 
depression (McKetin, Lubman, Lee, Ross & Slade, 2011). Given these findings and the 
evidence that methamphetamine users are likely to use multiple substances concurrently, 
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the relationship between methamphetamine use and depression may be moderated by 
polydrug use.  
The mesosystem (familial level) consists of the interrelations in major settings 
that contain the person at specific period of development and encompasses interactions 
between the individual and family, peer group and other caregivers (Bronfenbrenner, 
1977). Childhood maltreatment, specifically physical and sexual abuse, is a strong and 
consistent predictor of depression (Bifulco, Brown & Adler, 1991; Fletcher, 2009; 
Molnar, Buka & Kessler, 2001) and is highly correlated with adult substance use (Dube 
et al., 2003; Kendall-Tackett, 2002; Nelson et al., 2002; Silverman, Reinherz, & 
Giaconia, 1996). Brown and colleagues (1999) conducted a prospective cohort study with 
a sample of 776 individuals. After controlling for contextual factors, including family 
environment and parent and child characteristics, young adults who experienced 
childhood maltreatment were nearly four times more likely to be depressed compared to 
young adults with no history of childhood maltreatment (Brown, Cohen, Johnson & 
Smailes, 1999). In considering the association between methamphetamine use and 
depression, childhood maltreatment may be a moderator.  
The exosystem (community level), an extension of the mesosystem, contains both 
formal and informal social structures that do not necessarily contain the individual, but 
rather impinge on the immediate settings of that person, ultimately influencing, 
delimiting, or even determining what occurs there (Bronfenbrenner, 1977). Functional 
poverty, an exosystem level variable, is associated with increased odds of 
methamphetamine use (Iritani, et al., 2007) and there is also evidence that it is associated 
with an increased risk of depression (Riolo, Nguyen, Greden & King, 2005). 
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In addition, there are several variables that should be considered covariates as 
previous research has identified each as a risk factor associated with methamphetamine 
use or depression. For example, age is a well-established risk factor associated with 
depression, with higher rates observed among young adults (Blazer, Kessler, McGonagle, 
& Swartz, 1994) and Whites, compared to other minorities, are more likely to be 
depressed (Kessler, et al., 1997; Riolo, Nguyen, Greden & King, 2005). Lastly, people 
living in the western United States and the South are more likely to be methamphetamine 
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CHAPTER 3: METHODS 
Description of the Data 
The National Longitudinal Study of Adolescent Health is a prospective cohort 
study of a nationally-representative sample designed to evaluate how social environments 
and behaviors in adolescence are associated with health and other outcomes into 
adulthood (Harris, et al., 2009). The Add Health project was directed by Kathleen Mullan 
Harris and designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at 
the University of North Carolina at Chapel Hill, and funded by the Eunice Kennedy 
Shriver National Institute of Child Health and Human Development, with cooperative 
funding from 23 other federal agencies and foundations. Access to Add Health restricted-
use data is available by contractual agreement with the Inter-University Consortium for 
Political and Social Research (ICPSR) through the Data Sharing for Demographic 
Research (DSDR) archive.   
Sampling Procedures 
As the largest, most comprehensive, longitudinal study of adolescents, Add 
Health began in 1994, with the identification of a sample consisting of 80 high schools 
and 52 middle schools with unequal probability of selection (Harris, et al., 2009). For the 
school sample, high school eligibility was determined by having an 11th grade and an 
enrollment of at least thirty students. The schools were stratified by region, school type 
(public, private, parochial), urbanity, ethnic mix, and size. One feeder school (typically a 
middle school, as eligibility was determined by inclusion of a 7th grade) for each high 
school was recruited, unless the high school included 7th grade. More than 70 percent of 
schools identified agreed to participate in the study, which resulted in a total of 132 
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schools associated with 80 different communities. Schools that declined were replaced 
with a school in the same stratum.   
From September 1994 until April 1995 (Wave I), in-school questionnaires were 
administered within a single 45- to 60-minute class period to more than 90,000 students. 
Survey questions included measurement of future expectations, school activities, 
friendship networks, and various health conditions. Using school enrollment data as the 
sampling frame for the in-home interview, students were stratified in each school by 
grade and sex, and about 17 students from each strata (a total of approximately 200 
adolescents from each pair of schools) were randomly chosen to form a core sample for 
home surveys of 12,105 students (participation in the in-school survey did not affect 
eligibility for inclusion in the in-home interview sample) (Harris, et al., 2009).  
Supplemental samples were created using responses to the in-school survey and 
participants were selected based on ethnicity (Cuban, Puerto Rican, and Chinese), genetic 
relatedness to siblings (e.g. twins, full siblings, half siblings), and adoption status and 
disability. Black adolescents with highly-educated parents were also oversampled 
(Harris, et al., 2009). The core sample and additional special samples yielded a sample 
size of 20,745 adolescents for the Wave I in-home interview, and this sample is the basis 
for all subsequent waves of data collection (Harris, et al., 2009).  
Survey Design 
The in-home interview, administered in 1994-95, included sections on family and 
peer relationships, risk-taking behaviors (including substance use, delinquency, and 
sexual-risk behaviors), and general health. The in-home survey also included a 30-minute 
parent interview (typically completed by the resident mother) that asked questions about 
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health conditions, relationships, employment, income, education, parent-teen 
communication and interaction, and neighborhood characteristics; approximately 85% of 
the parents of participants completed the parental supplement (Harris, et al., 2009). One 
year later, in 1996, the Wave II in-home interview was conducted with the 14,738 
adolescents from the original sample of 20,745 participants (Harris, et al., 2009).  
In 2001-02, respondents (now ages 18-28) were contacted, and 76% (N=15,197) 
of the original sample completed a follow-up survey (Wave III). Data were collected 
regarding health and related behaviors, access and use of healthcare services, sexual 
behavior, mental health, substance use, delinquency and violence. The Wave III in-home 
questionnaire also included questions about family relationships, mentoring relationships, 
personal income, civic participation, criminal justice involvement and religion and 
spirituality. In addition, retrospective questions were asked about childhood maltreatment 
prior to grade six (including neglect, physical, and sexual abuse).   
For the most recent follow-up (Wave IV, conducted between 2007-08 with 
participants now ages 24-34) the Add Health team located 92.5% of the original sample 
members and completed interviews with approximately 80% (n=15,709). In Wave IV, 
data was collected on sections included in previous waves, to maintain the longitudinal 
design of the survey. Expanded questions on substance use, including criteria for abuse 
and dependence, were added to Wave IV, in addition to several other domains, such as 
measure of personality dimensions, interpersonal and occupational stressors, and work 
and family responsibilities.  
All in-home interviews at each wave were completed on a laptop computer 
(supplied by the Add Health interviewer) and conducted in respondent’s home (though 
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this was not a requirement, and Add Health interviewers made arrangements with a 
handful of participants to complete the interview at a location that better accommodated 
the participant’s schedule). Less sensitive questionnaire sections were completed with the 
assistance of an interviewer (computer-assisted personal interview), and the more 
sensitive sections were administered using audio-computer assisted self interview 
(ACASI) technology. ACASI is an interview technique that uses a laptop computer and 
headphones to provide a spoken recording of each question as it is presented on the 
screen. Responses to questions are entered directly into the computer by the participant. 
This format provides more privacy than the standard questionnaire format and helps 
reduce self-report bias for sensitive behaviors (e.g. substance use and high-risk sexual 
behaviors).  
Analytic Sample 
This study examined young adult past year methamphetamine use (independent 
variable) at Wave III (2001-02) and later depression (dependent variable) at Wave IV 
(2007-08). Combining these two waves, the initial sample size started with N=17,864 and 
was reduced to n=13,034 after all unmatched cases were dropped. To examine 
longitudinal associations, only respondents with valid weights, cluster and strata values 
were included in the sample (n=9,421), and only respondents with non-missing responses 
for the independent and dependent variables were retained in the analytic sample 
(n=9,309). T-tests revealed that those with missing values and those with no missing 
values were not significantly different on key variables, such as gender, race/ethnicity, 
and functional poverty. For all variables that were tested as moderators or used as 
covariates, as is standard practice, if less than 5% of the data were missing, the missing 
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values were replaced with the mode for categorical variables (gender, race/ethnicity, US 
region, polydrug use, and functional poverty) and the mean for continuous variables 
(age). Childhood maltreatment had 7% missing and therefore, these cases were dropped 
from the analytic sample. T-tests revealed that there were no significant differences on 
key variables between those included in the analytic sample and those who were dropped, 
except that those missing were more likely to be male (p<0.05). As a result, the final 
analytic sample used to examine the associations between methamphetamine use and 
depression for all logistic regressions in this study was n=8,688. 
Variables  
In the current study, the independent variable, methamphetamine use, was 
measured by past year crystal meth use; the dependent variable, depression, was based on 
CES-D scores; four variables were tested as potential moderators (gender, functional 
poverty, polydrug use, and childhood maltreatment), and there were four additional 
covariates (age, race/ethnicity, US region, and Wave III depression) (Figure 2).  
Figure 2. Conceptual Model: The Relationship Between Methamphetamine Use and 
Depression
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Independent Variable: Methamphetamine Use (Wave III) 
Past Year Methamphetamine Use. Respondents were asked, “Have you used 
crystal meth in the past year?” Those who reported use in the past year were considered 
past year crystal methamphetamine users and responses were coded dichotomously 
(“yes” versus “no,” the referent). 
Dependent Variable: Depression (Wave IV) 
Depression. To measure depression, the Add Health interview contains a 9-item 
depressive symptoms scale modified from the 20-item Center for Epidemiologic Studies 
Depression Scale (CES-D) (Radloff, 1977; Santor & Coyne, 1997). Respondents were 
asked to indicate the frequency with which they experienced certain feelings in the past 
seven days. The feelings statements included: “You were bothered by things that don’t 
usually bother you. You could not shake off the blues, even with help from your family 
and friends. You felt you were just as good as other people. You had trouble keeping your 
mind on what you were doing. You felt depressed. You felt that you were too tired to do 
things. You felt happy. You enjoyed life. You felt sad.” Response options were 0 (never or 
rarely), 1 (some or little of the time), 2 (occasionally or a moderate amount of time), and 
3 (most of the time or all the time) and were summed to produce a score between 0 and 
27. Following the methods of previous researchers, a cut-off score was used to determine 
whether a respondent is “depressed” based on the top quintile of the distribution of CES-
D scores as determined in initial analyses (Cesur, Sabia, & Tekin, 2011; Goodman & 
Capitman, 2000; Tekin, Erdal & Markowitz, 2008) and coded dichotomously 
(“depressed” versus “not depressed,” the referent). In this sample a score of 13 was used 
to determine the cut-off for the top quintile of scores. Therefore, a score of 13 or greater 
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was coded as “depressed” and a score of 12 or less was coded as “not depressed,” the 
referent. 
Moderator Variables (Wave III) 
Gender. Gender was based on respondent self-report at Wave III. Responses were 
coded dichotomously (“male” or “female,” the referent).  
Functional Poverty Status. At Wave III, respondents were asked, “In the past 12 
months, was there a time when you didn’t pay the full amount of the rent or mortgage 
because you didn’t have enough money?” and “In the past 12 months, was there a time 
when you didn’t pay the full amount of a gas, electricity, or oil bill?” Responses were 
coded dichotomously (“yes” versus “no,” the referent) and low functional poverty status 
was defined by an affirmative response to either question.  
Polydrug Use. Respondents were asked, “In the past year have you used 
marijuana? Any kind of cocaine – including crack, freebase or powder? Any other types 
of illegal drugs, such as LSD, PCP, ecstasy, mushrooms, inhalants, ice, heroin, or 
prescription medicines not prescribed for you?” An affirmative response for two or more 
of the substance use questions was coded as 1 (“yes”) and responses of one or zero were 
coded 0 (“no”).  
History of Childhood Maltreatment. At Wave III, respondents were asked 
retrospectively about childhood maltreatment that occurred by the sixth grade. Neglect 
was measured by asking, “How often had your parents or other adult caregivers left you 
home alone when an adult should have been with you?” and “How often had your 
parents or other adult caregivers not taken care of your basic needs, such as keeping you 
clean or providing food or clothing?” Physical abuse was measured by asking 
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respondents, “How often had your parents or other adult caregivers slapped, hit or 
kicked you?” Based on the methods of Currie and Tekin (2006) responses were coded 
dichotomously (“yes” versus “no,” the referent) if the respondent reports 10 or more 
occurrences of neglect and/or physical abuse.  Sexual abuse was measured using the 
following question, “How often had one of your parents or other adult caregivers 
touched you in a sexual way, forced you to touch him or her in a sexual way, or forced 
you to have sexual relations?” Responses to this item were coded “yes” if the respondent 
reports any instance of sexual abuse, versus “no” (none), the referent. Together, these two 
items were combined to generate a single variable called “childhood maltreatment” and 
coded dichotomously, “yes” vs. “no,” the referent.  
Covariates (Wave III) 
Age. Age, a continuous variable, was measured at Wave III based on self-report.  
Race/Ethnicity. Race/ethnicity is a nominal variable that was categorized based 
on respondent self-report. Respondents were coded as either “White” (the referent), 
“African American,” “Latino,” “Native American,” or “Asian American.”  
US Region. US region is a categorical variable. Add Health assigns the 
corresponding US census region (“West,” “South,” “Midwest” or “Northeast,” the 
referent) based on respondents’ address of residence. 
Depression. Wave III depression was also measured using the CES-D and the 
same methods as Wave IV depression as described above. However, based on the 
distribution of the responses, a cut-off score of 9 was used to represent the top quintile or 
“depressed” respondents. Those with a score of 8 or below were coded as “not 
depressed,” the referent.  
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Data Analysis  
All analyses were conducted using Stata version 11.0 (Stata Corp., College 
Station, TX, USA). In Stata, survey commands were used to account for stratification and 
clustering. Unequal selection probability were used, and appropriate weights were 
applied to ensure a nationally-representative sample. Descriptive statistics were 
conducted for all study variables. For continuous variables (e.g., age), means and 
confidence intervals were reported. Categorical variables (e.g., gender, race/ethnicity, 
functional poverty, etc.) were reported using weighted frequencies.  
Research Question 1a: What is the longitudinal association between 
methamphetamine use at Wave III (2001-02) and depression at Wave IV (2007-
08)? 
Research Question 1b: What is the longitudinal association between 
methamphetamine use at Wave III (2001-02) and depression at Wave IV (2007-
08), controlling for depression at Wave III? 
 
Logistic regressions were used to estimate the unadjusted odds ratios and 95% 
confidence intervals for the associations between methamphetamine use and depression. 
Adjusted ORs and 95% CIs (controlling for gender, age, race/ethnicity, US region, 
functional poverty, childhood maltreatment, polydrug use, and Wave III depression) for 
the associations between methamphetamine use and depression were examined and 
reported.  
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Research Question 2: Is the relationship between methamphetamine use (at Wave 
III) and depression (at Wave IV) moderated by gender, functional poverty, 
childhood maltreatment, or polydrug use? 
To examine whether the association between methamphetamine use and 
depression differed by gender, functional poverty status, polydrug use, or childhood 
maltreatment, an interaction term was tested for significance (p<0.05).  If the interaction 
term was significant then the variable was considered to be a moderator of the 
association.  
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CHAPTER 4: RESULTS 
Population Sociodemographic Characteristics 
 A total of 8,688 individuals were included in the final analytic sample. Table 1 
illustrates the sample characteristics on key variables. A little more than half of the 
respondents were female (51%). The majority of respondents were white (69%), African 
American (15%), or Latino (12%), and a small proportion were Asian American (3%) or 
Native American (<1%). At Wave III, the mean age of respondents was 21.6 years 
(SD=1.63). The largest proportion of respondents resided in the South (39%) and nearly a 
third lived in the Midwest (32%); remaining respondents were from the West (17%) or 
Northeast (13%). Approximately 14% of the analytic sample met criteria for functional 
poverty. About 36% reported polydrug use, and nearly 18% had experienced childhood 
maltreatment. 
Sociodemographic Characteristics of Methamphetamine Users 
In this study, 2.9% (n=243) of the young adults (ages 18-28) interviewed at Wave 
III, reported past year methamphetamine use (Table 1). Methamphetamine users were 
twice as likely to be male (OR: 2.00, 95% CI: 1.35-2.97). Compared to Whites, only 
Native Americans had an increased risk of methamphetamine use (OR: 2.59, 95% CI: 
1.07-6.29), however the confidence interval was wide and the elevated odds ratio may be 
a result of the small number of Native Americans in the sample (n=77). Age was 
categorized into three groups, 18-20 years, 21-22 years, and 23-28 years based on 
distribution, and no age group was significantly more likely to use methamphetamine. 
Methamphetamine users were most likely to live in the West (OR: 4.06, 95% CI: 1.94-
8.52) or South (OR: 2.19, 95% CI: 1.05-4.55), compared to the Midwest or Northeast.  
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Table 1. Associations Between Respondent Characteristics and Methamphetamine Use 
among Young Adults (N=8,688) ages 18-28, in the United States (US)† 
  N=8,688 Weighted % 
Weighted % of 
Past Year Meth 
Use (n=243) 
Unadjusted Odds Ratios  
(95% Confidence 
Intervals) 
Gender     
Female 4,829 51.0% 2.0% Referent 
Male 3,859 49.0% 3.9% 2.00 (1.35-2.97) 
Race     
White 4,994 68.8% 3.6% Referent 
African American 1,778 15.2% 0.3% 0.08 (0.03-0.23) 
Latino 1,317 12.0% 2.1% 0.57 (0.28-1.16) 
Native American 77 0.7% 8.8% 2.59 (1.07-6.29) 
Asian 522 3.3% 2.0% 0.54 (0.21-1.35) 
Age (Years)     
Mean 21.6 (21.58-21.65)   
18-20 2,373 33.9% 3.0% Referent 
21-22 3,474 38.4% 3.2% 1.06 (0.69-1.64) 
23-28 2,841 27.7% 2.3% 0.75 (0.45-1.24) 
Region     
Northeast 1,059 13.2% 1.3% Referent 
Midwest 2,366 31.6% 2.6% 1.99 (0.96-4.13) 
South 3,227 38.5% 2.8% 2.19 (1.05-4.55) 
West 2,036 16.7% 5.1% 4.06 (1.94-8.52) 
Functional Poverty     
No 7,513 86.5% 2.7% Referent 
Yes 1,175 13.5% 4.1% 1.55 (1.02-2.36) 
Polydrug Use     
No 5,788 64.0% 0.1% Referent 
Yes 2,900 36.0% 7.8% 67.00 (28.66-156.63) 
Childhood Maltreatment     
No  7,080 82.4% 2.2% Referent 
Yes 1,608 17.6% 6.1% 2.88 (2.11-3.92) 
†Survey commands accounting for stratification, clustering, and unequal selection probabilities 
yielded nationally representative estimates. 
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Methamphetamine users were more likely to live in functional poverty (OR: 1.55, 95% 
CI: 1.02-2.36) compared to non-users, and were much more likely to use other illicit 
drugs (OR: 67.00, 95% CI: 28.66-156.63). Methamphetamine users were nearly three 
times more likely to experience childhood maltreatment compared to non-users (OR: 
2.88, 95% CI: 2.11-3.92). 
Associations Between Methamphetamine Use and Depression 
Model 1. Unadjusted analyses showed that Wave III methamphetamine use was 
associated with an increased risk of depression at Wave IV (OR: 2.13, 95% CI: 1.38-
3.27) (Table 2, Model 1). 
Model 2. Adjusted analyses (controlling for gender, age, race/ethnicity, US 
region, functional poverty, polydrug use, and childhood maltreatment) revealed that 
Wave III methamphetamine use was an independent predictor of Wave IV depression 
(AOR: 2.04, 95% CI: 1.29-3.21) (Table 2, Model 2). 
 Covariates. In this model, being African American, living in functional poverty, 
and experiencing childhood maltreatment were all variables associated with increased 
risk of depression at Wave IV.  
Model 3. Adjusted analyses controlling for Wave III depression revealed that 
Wave III methamphetamine use was associated with an increased risk of depression at 
Wave IV (AOR: 1.78, 95% CI: 1.14-2.76) (Table 2, Model 3). Covariates. In this model, 
only Wave III depression was used as a covariate, and it was associated with more than 
five times the likelihood of Wave IV depression (Table 2, Model 3). Model 4. Adjusted 
analyses (controlling for Wave III depression, gender, age, race/ethnicity, US region, 
functional poverty, polydrug use, and childhood maltreatment) showed that Wave III  
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Table 2. Associations Between Methamphetamine Use and Depression Among Young 
Adults(N=8,688) in the US† 
  Model 1 Model 2 Model 3 Model 4 
Exposure     
Wave III Meth 2.13 (1.38-3.27) 2.04 (1.29-3.21) 1.78 (1.14-2.76) 1.81 (1.12-2.92) 
Covariates     
Wave III Depression   5.30 (4.17-6.74) 4.69 (3.65-6.03) 
Gender      
Female  Referent  Referent 
Male  0.53 (0.41-0.68)  0.60 (0.47-0.77) 
Age       
18-20  Referent  Referent 
21-22  1.10 (0.84-1.44)  1.08 (0.83-1.41) 
23-28  1.11 (0.84-1.48)  1.19 (0.89-1.59) 
Race       
White  Referent  Referent 
African American  1.80 (1.19-2.72)  1.64 (1.10-2.42) 
Latino  0.99 (0.72-1.36)  0.83 (0.59-1.17) 
Native American  1.31 (0.37-3.49)  1.15 (0.42-3.12) 
Asian  0.81 (0.46-1.44)  0.73 (0.43-1.26) 
US Region       
Northeast  Referent  Referent 
Midwest  0.98 (0.55-1.73)  1.06 (0.61-1.84) 
South  1.00 (0.53-1.89)  1.05 (0.57-1.93) 
West  0.94 (0.52-1.69)  0.95 (0.53-1.67) 
Functional Poverty       
No   Referent  Referent 
Yes  1.72 (1.30-2.27)  1.40 (1.05-1.86) 
Polydrug Use     
No   Referent  Referent 
Yes  1.27 (0.99-1.63)  1.18 (0.92-1.51) 
Childhood 
Maltreatment     
No   Referent  Referent 
Yes   1.54 (1.19-1.99)   1.32 (1.02-1.71) 
†Survey commands accounting for stratification, clustering, and unequal selection probabilities 
yielded nationally representative estimates. 
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methamphetamine use was an independent predictor of Wave IV depression (AOR: 1.81, 
95% CI: 1.12-2.92) (Table 2, Model 4). 
Covariates. In this model, Wave III depression, being African American, living in 
functional poverty, and experiencing childhood maltreatment were all associated with 
increased risk of depression at Wave IV (Table 2, Model 4). 
Associations Between Methamphetamine Use and Depression, with Gender as a 
Moderator 
 Model 1. Adjusted analyses, controlling for gender, revealed that Wave III 
methamphetamine use was associated with an increased risk of Wave IV depression 
(AOR: 2.39, 95% CI: 1.55-3.67).  
Moderator. The interaction term for gender was not significant. 
Model 2. Adjusted analyses (covariates included gender, age, race/ethnicity, US 
region, functional poverty, polydrug use, and childhood maltreatment) revealed that 
methamphetamine use at Wave III was an independent predictor of subsequent 
depression at Wave IV (AOR: 2.04, 95% CI: 1.29-3.21) (Table 3, Model 2). 
 Moderator. The interaction term for gender was not significant.  
Covariates. In this model, being African American, living in functional poverty, 
and experiencing childhood maltreatment were all associated with an increased likelihood 
of depression at Wave IV (Table 3, Model 2). 
Model 3. Adjusted analyses, controlling for gender and Wave III depression, 
revealed that Wave III methamphetamine use was associated with an increased likelihood 
of Wave IV depression (AOR: 1.90, 95% CI: 1.20-3.00) (Table 3, Model 3). 
Moderator. The interaction term for gender was not significant.  
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Table 3. Associations Between Methamphetamine Use and Depression Among Young 
Adults (N=8,688) in the US, with Gender as a Moderator† 
  Model 1 Model 2 Model 3 Model 4 
Exposure 
    Wave III Meth 2.87 (1.71-4.81) 2.40 (1.38-4.17) 1.88 (1.03-3.43) 1.78 (0.97-3.27) 
Hypothesized Moderator 
    Gender 0.54 (0.42-0.70) 0.54 (0.42-0.70) 0.61 (0.47-0.79) 0.60 (0.46-0.77) 
Interaction Term 
    MethXGender 0.70 (0.30-1.65) 0.73 (0.31-1.71) 1.03 (0.42-2.51) 1.04 (0.44-2.46) 
Covariates 
    Wave III Depression 
  
5.05 (3.95-6.46) 4.69 (3.64-6.04) 
Age 
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Covariates. In this model, Wave III depression was associated with an increased 
likelihood of Wave IV depression (Table 3, Model 3). 
Model 4. Adjusted analyses, controlling for covariates and Wave III depression), 
revealed that methamphetamine use at Wave III was predictive of Wave IV depression 
(AOR: 1.81, 95% CI: 1.12-2.92) (Table 3, Model 4). 
Moderator. The interaction term for gender was not significant. 
Covariates. In this model, Wave III depression, being African American, living in 
functional poverty, and experiencing childhood maltreatment were all variables 
associated with an increased risk of depression at Wave IV (Table 3, Model 4). 
Associations Between Methamphetamine Use and Depression, with Functional 
Poverty as a Moderator 
 Model 1. Adjusted analyses, controlling for functional poverty, revealed that 
Wave III methamphetamine use was associated with an increased likelihood of 
depression at Wave IV (AOR: 2.03, 95% CI: 1.31-3.17) (Table 4, Model 1).  
Moderator. The interaction term for functional poverty was not significant (Table 
4, Model 1). 
 Covariates. In this model, functional poverty was associated with an increased 
risk of depression at Wave IV (Table 4, Model 1). 
 Model 2. Adjusted analyses, controlling for functional poverty, gender, age, 
race/ethnicity, US region, polydrug use and childhood maltreatment, revealed that 
methamphetamine use was an independent predictor of Wave IV depression (AOR: 2.04, 
95% CI: 1.29-3.21) (Table 4, Model 2). 
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Table 4. Associations Between Methamphetamine Use and Depression Among Young 
Adults (N=8,688) in the US, with Functional Poverty as a Moderator† 
  Model 1 Model 2 Model 3 Model 4 
Exposure 
    Wave III Meth 2.29 (1.36-3.87) 2.26 (1.31-3.88) 1.87 (1.11-3.15) 1.90 (1.09-3.33) 
Hypothesized Moderator 
    Functional Poverty 2.18 (1.65-2.89) 1.76 (1.31-2.36) 1.65 (1.23-2.21) 1.41 (1.05-1.90) 
Interaction Term 
    MethXFunctional Poverty 0.62 (0.20-1.91) 0.66 (0.22-1.96) 0.77 (0.27-2.23) 0.81 (0.29-2.28) 
Covariates 
    Wave III Depression 
  
5.00 (3.91-6.40) 4.68 (3.64-6.02) 
Gender 


























































































Yes   1.54 (1.19-1.99)   1.32 (1.02-1.71) 
†Survey commands accounted for stratification, clustering, and unequal selection probabilities yielded 
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Moderator. The interaction term for functional poverty was not significant.  
Covariates. In this model, living in functional poverty, being African American, 
and experiencing childhood maltreatment were all factors associated with an increased 
risk of depression at Wave IV (Table 4, Model 2). 
Model 3. Adjusted analyses, controlling for functional poverty and Wave III 
depression, revealed that Wave III methamphetamine use was associated with an 
increased likelihood of Wave IV depression (AOR: 1.76, 95% CI: 1.12-2.76) (Table 4, 
Model 3).  
Moderator. The interaction term for functional poverty was not significant. 
Covariates. In this model, both functional poverty and Wave III depression were 
associated with an increased likelihood of Wave IV depression (Table 4, Model 3). 
Model 4. Adjusted analyses, controlling for covariates and Wave III depression, 
revealed that methamphetamine use was an independent predictor of Wave IV depression 
(AOR: 1.81, 95% CI: 1.12-2.92) (Table 4, Model 4). 
Moderator. The interaction term for functional poverty was not significant. 
Covariates. In this model, functional poverty, Wave III depression, being African 
American, and experiencing childhood maltreatment were associated with an increased 
likelihood of Wave IV depression (Table 4, Model 4).  
Associations Between Methamphetamine Use and Depression, with Polydrug Use as 
a Moderator 
 Model 1. Adjusted analyses, controlling for polydrug use, revealed that Wave III 
methamphetamine use was associated with an increased likelihood of depression at Wave 
IV (AOR: 1.90, 95% CI: 1.23-2.94) (Table 5, Model 1).  
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Table 5. Associations Between Methamphetamine Use and Depression Among Young 
Adults (N=8,688) in the US, with Polydrug Use as a Moderator†  
  Model 1 Model 2 Model 3 Model 4 
Exposure 
    









    Polydrug Use* 1.22 (0.95-1.56) 1.29 (1.01-1.66) 1.12 (0.87-1.43) 1.20 (0.94-1.54) 
Interaction Term 
    MethXPolydrug Use 0.19 (0.03-1.15) 0.14 (0.02-1.06) 0.13 (0.02-0.84) 0.10 (0.01-0.73) 
 
Polydrug User:  
1.76 (1.13-2.76) 
Polydrug User:  
1.88 (1.17-3.01) 
Polydrug User: 
 1.54 (0.97-2.45) 



















    Wave III Depression 
  
5.29 (4.16-2.73) 4.71 (3.66-6.06) 
Gender 



























































































Yes   1.54 (1.19-1.99)   1.32 (1.02-1.70) 
†Survey commands accounted for stratification, clustering, and unequal selection probabilities yielded 
nationally representative estimates. 
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Moderator. The interaction term for polydrug use was significant at the 0.05 level. 
Methamphetamine users who were not polydrug users had higher increased odds of 
depression (AOR: 9.04, 95% CI 1.65-53.56) than polydrug using methamphetamine users 
(AOR: 1.76, 95% CI: 1.13-2.76). While methamphetamine only users appeared to be at a 
considerably higher risk of depression, being nine times more likely than poly-drug using 
methamphetamine users to become depressed, it is important to note the large confidence 
interval for this odds ratio, which may be a function of the small number of non-poly 
drug using meth users (n=8) (Table 5, Model 1). 
 Model 2. Adjusted analyses, controlling for all covariates, revealed that Wave III 
methamphetamine users are two times more likely to experience depression at Wave IV 
compared to non-methamphetamine users (AOR: 2.04, 95% CI: 1.29-3.21) (Table 5, 
Model 2).  
Moderator. The interaction term for polydrug use was significant at the 0.05 level. 
Methamphetamine users who were not polydrug users had thirteen times the odds of 
depression at Wave III (AOR: 13.03, 95% CI: 1.92-88.35). Methamphetamine users that 
were also polydrug users had increased odds of depression, though not as high as the non-
polydrug users (AOR: 1.88, 95% CI: 1.17-3.01) As mentioned above, it is important to 
note the wide confidence interval for non-polydrug methamphetamine users, noting that 
although they are thirteen times more likely to become depressed, this odds ratio may be 
a function of the small number of non-polydrug users (n=8) (Table 5, Model 2).  
Covariates. Being African American, living in functional poverty, and 
experiencing childhood maltreatment were all associated with Wave IV depression 
(Table 5, Model 2). 
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Model 3. Adjusted analyses, controlling for all polydrug use and Wave III 
depression, revealed that Wave III methamphetamine users have increased odds of 
depression at Wave IV compared to non-methamphetamine users (AOR: 1.68, 95% CI: 
1.07-2.64) (Table 5, Model 3). 
Moderator. The interaction term for polydrug use was significant at the 0.05 level. 
Methamphetamine users who were not polydrug users had nearly twelve times the odds 
of depression at Wave III (AOR: 11.68, 95% CI: 2.02-67.68). The odds ratio for polydrug 
users was not significant (AOR: 1.54, 95% CI: 0.97-2.45). Again, it should be noted that 
non-polydrug methamphetamine users had nearly twelve times the odds of becoming 
depressed, however the precision of the estimate may not be accurate as the confidence 
interval was wide and there were only 8 non-polydrug methamphetamine users (Table 5, 
Model 3). 
Covariates. In this model, Wave III depression was associated with an increased 
risk of depression at Wave IV (Table 5, Model 3). 
Model 4. Adjusted analyses, controlling for all covariates and Wave III 
depression, revealed that methamphetamine users were nearly two times more likely to 
be depressed at Wave IV compared to those who did not use methamphetamine (AOR: 
1.81, 95% CI: 1.12-2.92 (Table 5, Model 4). 
Moderator. The interaction term for polydrug use was significant at the 0.05 level. 
Methamphetamine users who were not polydrug users had sixteen times the odds of 
depression at Wave III (AOR: 16.08, 95% CI: 2.52-102.61). Non-polydrug 
methamphetamine users were less than two times as likely to be depressed at Wave IV 
(AOR: 1.65, 95% CI: 1.00-2.70). It is important to note the large confidence interval for 
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this odds ratio, which may be a function of the small number of non-poly drug using 
meth users (n=8) (Table 5, Model 4). 
Covariates. In this model, Wave III depression, being African American, living in 
functional poverty, and experiencing childhood maltreatment were all factors associated 
with Wave IV depression (Table 5, Model 4).  
Associations Between Methamphetamine Use and Depression, with Childhood 
Maltreatment as a Moderator 
 Model 1. Adjusted analyses, controlling for childhood maltreatment, revealed that 
methamphetamine use at Wave III was associated with an increased likelihood of 
depression at Wave IV (AOR: 1.91, 95% CI: 1.23-2.98) (Table 6, Model 1). 
Moderator. The interaction term for childhood maltreatment was not significant. 
 Covariates. In this model, experiencing childhood maltreatment was associated 
with an increased risk of depression at Wave IV (Table 6, Model 1). 
Model 2. Adjusted analyses (controlling for childhood maltreatment, gender, age, 
race/ethnicity, US region, functional poverty, and polydrug use) revealed that 
methamphetamine use at Wave III was associated with an increased risk of Wave IV 
depression (AOR: 2.04, 95% CI: 1.29-3.21) (Table 6, Model 2).  
Moderator. The interaction term for childhood maltreatment was not significant. 
 
Covariates. In this model, experiencing childhood maltreatment, being African 
American, and living in functional poverty were associated with an increased likelihood 
of depression at Wave IV (Table 6, Model 2).  
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Table 6. Associations Between Methamphetamine Use and Depression Among Young 
Adults (N=8,688) in the US, with Childhood Maltreatment as a Moderator† 
  Model 1 Model 2 Model 3 Model 4 
Exposure 
    Wave III Meth 2.38 (1.37-4.14) 2.49 (1.42-4.39) 2.05 (1.12-3.75) 2.24 (1.19-4.20) 
Hypothesized Moderator 
    Childhood Maltreatment 1.72 (1.34-2.20) 1.60 (1.23-2.07) 1.40 (1.09-1.79) 1.37 (1.06-1.77) 
Interaction Term 
    MethXChildhood Maltreatment 0.58 (0.22-1.50) 0.60 (0.23-1.56) 0.60 (0.23-1.53) 0.59 (0.23-1.51) 
Covariates 
    Wave III Depression 
  
5.14 (4.03-6.55) 4.69 (3.65-6.03) 
Gender 


























































































Yes   1.27 (0.99-1.63)   1.18 (0.92-1.51) 
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Moderator. The interaction term for childhood maltreatment was not significant. 
Covariates. In this model, experiencing childhood maltreatment and being 
depressed at Wave III were both factors associated with an increased likelihood of Wave 
IV depression (Table 6, Model 3). 
Model 4. Adjusted analyses, controlling for covariates and Wave III depression, 
revealed that methamphetamine use at Wave III is an independent predictor of depression 
at Wave IV (AOR: 1.81, 95% CI: 1.12-2.92) (Table 6, Model 4).   
Moderator. The interaction term for childhood maltreatment was not significant. 
Covariates. In this model, experiencing childhood maltreatment, being depressed 
at Wave III, being African American, and living in functional poverty were all associated 
with an increased risk of depression at Wave IV (Table 6, Model 4).  
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CHAPTER 5: DISCUSSION 
 
Summary of Findings and Implications 
This study used a nationally representative dataset of young adults, the age group 
most likely to use methamphetamine (SAMHSA, 2006), to examine the longitudinal 
relationship between past year methamphetamine use and depression. Although previous 
research has identified an association between methamphetamine use and depression, 
these studies typically involved clinical populations in treatment or criminal justice 
populations (Glasner-Edwards et al., 2008; Semple, Patterson & Grant, 2005; Zweben et 
al., 2004). To the author’s knowledge, no research exists examining the association 
between methamphetamine use and depression within the general population.  
Further, little is known about additional factors that may affect the relationship, 
variables that either increase the risk of depression or act as a buffer, potentially 
diminishing the risk of depression for methamphetamine users. In this study analyses 
were conducted to determine whether the association between methamphetamine use and 
depression exists within the general population and to examine how other factors may 
affect this relationship. The specific factors examined included gender, functional poverty 
status, polydrug use, and childhood maltreatment. 
Indeed, this study provides evidence that among methamphetamine users in the 
general population, methamphetamine use is associated with an increased risk of 
depression. Further, longitudinal analyses revealed that methamphetamine use is an 
independent predictor of future depression, when controlling for covariates including 
gender, age, race/ethnicity, US region, functional poverty, childhood maltreatment, and 
polydrug use. Lastly, analyses controlling for depression at Wave III revealed that 
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independent of depression status, methamphetamine users are more likely to be depressed 
at Wave IV (six years later).  
Additionally, aside from polydrug use, none of the other potential moderator 
variables were significant, and therefore, gender, functional poverty, and childhood 
maltreatment do not contribute to nor buffer against depression for methamphetamine 
users. Given these findings, designing interventions and treatment programs for 
depression that are targeted at specific populations of methamphetamine users may not be 
as important as incorporating mental health treatment for all methamphetamine users.  
In fact, given the increased risk for depression among methamphetamine users, 
individuals in treatment programs may benefit from focusing on mental health outcomes 
as part of substance abuse treatment interventions. At the very least, this study highlights 
the need for appropriate screening and diagnoses of depression among methamphetamine 
users and future studies focusing on outcomes for depressed methamphetamine users will 
provide a more complete picture of the problem.  
Polydrug use was found to be a moderator of depression, as exclusive 
methamphetamine users (those who were not polydrug users) were more likely to be 
depressed at Wave IV compared to polydrug users. However, the number of non-
polydrug methamphetamine users was very small (n=8), which resulted in a large 
confidence interval and imprecise measurement. Therefore this finding is suspect and  
warrants further investigation. 
The findings have several implications for future research. First, this study used 
Waves III (2001-02) and IV (2007-08) of Add Health, as it was the most comprehensive 
dataset available to answer the research questions. However, the six year time lapse 
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between waves allows for many other life events and changes, such as death of a loved 
one, divorce, or job loss. These factors may result in residual confounding. Future 
research should involve a time series design with more frequent measurement over the 
longitudinal period.  
Since this study controlled for many socio-behavioral factors associated with 
depression, these findings add further support to theories highlighting the role of the brain 
and neurocognitive functioning in depression among methamphetamine users. There is a 
body of research focused on the effects of methamphetamine abuse and dependence on 
the brain (see Meredith, et al., 2005); however, many of the published studies focus on 
clinical samples or criminal justice populations. Designing studies to look at 
methamphetamine users in the general population is warranted, given the findings of this 
study.  
The ecological model was used as a framework to guide the selection of different 
level variables to test as potential moderators. Although none of the variables tested were 
shown to moderate the association between methamphetamine use and depression, 
further research evaluating additional variables is warranted. The Add Health dataset is 
rich with information on microsystem level factors (e.g. criminal justice involvement), 
mesosystem level factors (e.g. relationship history), and exosystem level factors (e.g. 
neighborhood characteristics). In the Add Health data, information on macrosystem level 
variables is limited, however, it may be that the former mentioned levels are more 
appropriate for identifying information that can be used to develop prevention or 
treatment programs. Lastly, using the ecological model, several variables were tested as 
potential moderators of the relationship between methamphetamine use and depression; 
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however, it may be that another relationship, such as mediation, exists in these data. 
Additional research and analyses are needed to fully understand the association and how 
other factors may affect it.  
As previously stated, methamphetamine use is associated with significant physical 
and mental health consequences. Aneshensel and colleagues (1984) assessed physical 
health and depression among a community sample of 744 adults. Findings indicated that 
physical health problems were associated with increased levels of depression, even after 
controlling for previous depression (Aneshensel, Frerisch & Huba, 1984). The 
association between depression and physical illness has been described as a self-
perpetuating and mutually reinforcing process operating over time (Aneshensel, Frerisch 
& Huba, 1984). In terms of methamphetamine use, it is possible that the negative health 
consequences and physical ailments associated with use (e.g. hypertension, insomnia) 
lead to depression. This may be a potential area of future research. 
Limitations 
This study is not without limitations that must be noted. First, although the 
findings from this study are generalizable as the sample was nationally representative, it 
is likely that those with the most severe drug problems or mental health issues were not 
found for follow-up interview and the final sample may not accurately capture those with 
the most severe symptoms. Second, this study employed a broad measurement for 
methamphetamine use (any use in the past year) to generate a larger sample size. The 
methamphetamine use variable is simply “any use” and does not account for frequency or 
duration of use, nor does it allow for assumptions about abuse or dependence. Further 
research accounting for these factors will allow for better application of the findings. 
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Third, this study is based on self-report data, which may result in underreporting of 
socially undesirable behaviors, such as substance use and depressive symptoms. 
However, Add Health methodology includes precautions to increase confidentiality 
through the use of audio computer-assisted self-interview (A-CASI), which is associated 
with increased reporting of sensitive information (Turner, Ku, Lindberg, Pleck, & 
Sonenstein, 1998).  
Conclusions 
Despite the noted limitations, this study addresses a critical gap in the literature, 
as the findings establish that methamphetamine use increases the risk for later depression 
and even independently predicts future depression. In addition, this study revealed that 
certain factors, including gender, functional poverty, and childhood maltreatment, have 
no effect on the association between methamphetamine use and depression. Establishing 
the association between methamphetamine use and depression in a nationally 
representative sample, and identifying that the risk of depression is not moderated by 
several socio-behavioral factors, are necessary preliminary steps for developing and 
delivering interventions for both prevention and treatment purposes.  
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